STOCK TITAN

PMV Pharmaceuticals (PMVP) director awarded 42,000 stock options at $1.19

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PMV Pharmaceuticals director Kirsten Flowers received a stock option grant covering 42,000 shares of common stock. The options have an exercise price of $1.19 per share and expire on June 4, 2036. These options vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting.

Positive

  • None.

Negative

  • None.
Insider FLOWERS KIRSTEN
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 42,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 42,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 42,000 options Stock option grant to director Kirsten Flowers
Exercise price $1.19 per share Exercise price for granted stock options
Expiration date June 4, 2036 Option expiration for this grant
Post-grant option holdings 42,000 options Total options held following the transaction
Vesting date trigger June 4, 2027 Latest vesting date or earlier next annual meeting
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.1900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"Shares subject to the option vest on the earlier of (i) June 4, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"or (ii) the date of the Issuer's next annual meeting of stockholders."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FLOWERS KIRSTEN

(Last)(First)(Middle)
C/O PMV PHARMACEUTICALS, INC.
400 ALEXANDER PARK DRIVE, SUITE 301

(Street)
PRINCETON NEW JERSEY 08540

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.1906/04/2026A42,000 (1)06/04/2036Common Stock42,000$042,000D
Explanation of Responses:
1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
/s/ Robert Ticktin, by power of attorney06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PMVP director Kirsten Flowers report in this Form 4?

Director Kirsten Flowers reported receiving a grant of stock options for 42,000 shares of PMV Pharmaceuticals common stock. The grant is a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of the PMVP stock options granted to Kirsten Flowers?

The stock options granted to Kirsten Flowers have an exercise price of $1.19 per share. This means she can buy PMV Pharmaceuticals common stock at $1.19 when the options are vested and exercised, subject to the award’s expiration date.

When do Kirsten Flowers’ PMVP stock options vest?

The options vest on the earlier of June 4, 2027 or the date of PMV Pharmaceuticals’ next annual meeting of stockholders. Vesting determines when the director can exercise the options to acquire common shares at the fixed exercise price.

When do the PMVP stock options granted to Kirsten Flowers expire?

The options expire on June 4, 2036 if not exercised earlier. After that expiration date, Kirsten Flowers will no longer be able to use these options to purchase PMV Pharmaceuticals common stock at the $1.19 exercise price.

How many PMVP options does Kirsten Flowers hold after this grant?

Following this grant, the Form 4 shows Kirsten Flowers holding 42,000 stock options. Each option is linked to one share of PMV Pharmaceuticals common stock, subject to vesting terms and the stated exercise and expiration conditions.